Personified Approaches to Reperfusion Therapy of Ischemic Stroke View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-12

AUTHORS

M. A. Domashenko, M. Yu. Maksimova, M. E. Gafarova, M. M. Tanashyan, K. V. Antonova, M. A. Piradov

ABSTRACT

Introduction: Systemic thrombolytic therapy (STLT) with recombinant tissue plasminogen activator (rtPA) is the “gold standard” of reperfusion therapy in certain patients with ischemic stroke during the first 4.5 h after stroke onset. Objective: To assess the clinical (severity of neurological symptoms) and laboratory (complete blood cell count test) factors that affect the disease outcome after STLT. Materials and methods: Seventy patients (48 males and 22 females) aged 61 [54; 69] years with ischemic stroke who received rtPA therapy at a dose of 0.9 mg/kg were prospectively studied. Blood for the complete blood count test including neutrophil and lymphocyte counts was sampled before the thrombolytic therapy. The severity of neurological impairment was assessed using the NIH Stroke Scale (NIHSS). The functional outcome was assessed 3 months after stroke with the modified Rankin scale (mRS). ROC analysis was used to reveal factors of unfavorable outcome in acute phase of ischemic stroke (mRS score ≥ 3). Results: Severity of neurological deficit was assessed according to the NIHSS at admission was 15 [11; 17] points. Time between the manifestation of neurological symptoms and admission to the hospital was 138 [117; 170] min, and time between admission and initiation of STLT (the door-to-needle time), was 40 [30; 55] min. An unfavourable functional outcome of systemic thrombolytic therapy can be predicted according to the results of ROC analysis: the NIHSS score upon admission 12 or higher (sensitivity, 94%; specificity, 57%); neutrophil count, >7.8 × 109/L (sensitivity, 45.5%; specificity, 90.6%); lymphocyte count < 1.8 × 109/L (sensitivity, 81.8%; specificity, 59.4%). Conclusions: Personalized approach to systemic thrombolytic therapy may help to predict its effectiveness and contribute the development of more reliable strategies of patient management. Patients with potentially unfavorable outcome after intravenous thrombolysis can be the target group for mechanical reperfusion techniques such as thrombus extraction. More... »

PAGES

869-874

Identifiers

URI

http://scigraph.springernature.com/pub.10.1134/s0362119718080030

DOI

http://dx.doi.org/10.1134/s0362119718080030

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1112766608


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1102", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Cardiorespiratory Medicine and Haematology", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Botkin City Clinical Hospital, 125284, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.477034.3", 
          "name": [
            "Botkin City Clinical Hospital, 125284, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Domashenko", 
        "givenName": "M. A.", 
        "id": "sg:person.011622234404.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011622234404.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Center of Neurology, 125367, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465332.5", 
          "name": [
            "Research Center of Neurology, 125367, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Maksimova", 
        "givenName": "M. Yu.", 
        "id": "sg:person.01060542443.55", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060542443.55"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Vorokhobov City Clinical Hospital no. 67, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.477034.3", 
          "name": [
            "Vorokhobov City Clinical Hospital no. 67, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gafarova", 
        "givenName": "M. E.", 
        "id": "sg:person.010223501057.42", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010223501057.42"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Center of Neurology, 125367, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465332.5", 
          "name": [
            "Research Center of Neurology, 125367, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tanashyan", 
        "givenName": "M. M.", 
        "id": "sg:person.0577166305.86", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577166305.86"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Center of Neurology, 125367, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465332.5", 
          "name": [
            "Research Center of Neurology, 125367, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Antonova", 
        "givenName": "K. V.", 
        "id": "sg:person.015231126745.66", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015231126745.66"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Research Center of Neurology, 125367, Moscow, Russia", 
          "id": "http://www.grid.ac/institutes/grid.465332.5", 
          "name": [
            "Research Center of Neurology, 125367, Moscow, Russia"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Piradov", 
        "givenName": "M. A.", 
        "id": "sg:person.010206350616.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010206350616.20"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "sg:pub.10.1007/s00234-002-0762-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029241563", 
          "https://doi.org/10.1007/s00234-002-0762-6"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "Introduction: Systemic thrombolytic therapy (STLT) with recombinant tissue plasminogen activator (rtPA) is the \u201cgold standard\u201d of reperfusion therapy in certain patients with ischemic stroke during the first 4.5 h after stroke onset. Objective: To assess the clinical (severity of neurological symptoms) and laboratory (complete blood cell count test) factors that affect the disease outcome after STLT. Materials and methods: Seventy patients (48 males and 22 females) aged 61 [54; 69] years with ischemic stroke who received rtPA therapy at a dose of 0.9 mg/kg were prospectively studied. Blood for the complete blood count test including neutrophil and lymphocyte counts was sampled before the thrombolytic therapy. The severity of neurological impairment was assessed using the NIH Stroke Scale (NIHSS). The functional outcome was assessed 3\u00a0months after stroke with the modified Rankin scale (mRS). ROC analysis was used to reveal factors of unfavorable outcome in acute phase of ischemic stroke (mRS score \u2265 3). Results: Severity of neurological deficit was assessed according to the NIHSS at admission was 15 [11; 17] points. Time between the manifestation of neurological symptoms and admission to the hospital was 138 [117; 170] min, and time between admission and initiation of STLT (the door-to-needle time), was 40 [30; 55] min. An unfavourable functional outcome of systemic thrombolytic therapy can be predicted according to the results of ROC analysis: the NIHSS score upon admission 12 or higher (sensitivity, 94%; specificity, 57%); neutrophil count, >7.8 \u00d7 109/L (sensitivity, 45.5%; specificity, 90.6%); lymphocyte count < 1.8 \u00d7 109/L (sensitivity, 81.8%; specificity, 59.4%). Conclusions: Personalized approach to systemic thrombolytic therapy may help to predict its effectiveness and contribute the development of more reliable strategies of patient management. Patients with potentially unfavorable outcome after intravenous thrombolysis can be the target group for mechanical reperfusion techniques such as thrombus extraction.", 
    "genre": "article", 
    "id": "sg:pub.10.1134/s0362119718080030", 
    "inLanguage": "en", 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1085127", 
        "issn": [
          "0362-1197", 
          "1608-3164"
        ], 
        "name": "Human Physiology", 
        "publisher": "Pleiades Publishing", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "8", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "44"
      }
    ], 
    "keywords": [
      "systemic thrombolytic therapy", 
      "NIH Stroke Scale", 
      "recombinant tissue plasminogen activator", 
      "modified Rankin Scale", 
      "ischemic stroke", 
      "thrombolytic therapy", 
      "reperfusion therapy", 
      "lymphocyte count", 
      "functional outcome", 
      "unfavorable outcome", 
      "unfavourable functional outcome", 
      "ROC analysis", 
      "complete blood count test", 
      "blood count test", 
      "tissue plasminogen activator", 
      "intravenous thrombolysis", 
      "NIHSS score", 
      "stroke onset", 
      "Stroke Scale", 
      "Rankin Scale", 
      "neurological deficits", 
      "neutrophil count", 
      "reperfusion techniques", 
      "acute phase", 
      "neurological symptoms", 
      "thrombus extraction", 
      "rtPA therapy", 
      "certain patients", 
      "neurological impairment", 
      "laboratory factors", 
      "disease outcome", 
      "patient management", 
      "therapy", 
      "personified approach", 
      "stroke", 
      "personalized approach", 
      "patients", 
      "admission", 
      "plasminogen activator", 
      "gold standard", 
      "outcomes", 
      "count test", 
      "severity", 
      "counts", 
      "thrombolysis", 
      "target group", 
      "min", 
      "symptoms", 
      "hospital", 
      "neutrophils", 
      "dose", 
      "blood", 
      "impairment", 
      "months", 
      "manifestations", 
      "factors", 
      "scores", 
      "onset", 
      "deficits", 
      "group", 
      "reliable strategy", 
      "years", 
      "initiation", 
      "activator", 
      "management", 
      "time", 
      "test", 
      "scale", 
      "analysis", 
      "development", 
      "strategies", 
      "effectiveness", 
      "standards", 
      "results", 
      "approach", 
      "technique", 
      "method", 
      "point", 
      "materials", 
      "phase", 
      "extraction", 
      "initiation of STLT", 
      "admission 12", 
      "mechanical reperfusion techniques"
    ], 
    "name": "Personified Approaches to Reperfusion Therapy of Ischemic Stroke", 
    "pagination": "869-874", 
    "productId": [
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1112766608"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1134/s0362119718080030"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1134/s0362119718080030", 
      "https://app.dimensions.ai/details/publication/pub.1112766608"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2021-11-01T18:33", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-springernature-scigraph/baseset/20211101/entities/gbq_results/article/article_762.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://doi.org/10.1134/s0362119718080030"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1134/s0362119718080030'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1134/s0362119718080030'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1134/s0362119718080030'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1134/s0362119718080030'


 

This table displays all metadata directly associated to this object as RDF triples.

186 TRIPLES      22 PREDICATES      111 URIs      102 LITERALS      6 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1134/s0362119718080030 schema:about anzsrc-for:11
2 anzsrc-for:1102
3 schema:author N1c2d96b8b1a84911bec9e40b310df28f
4 schema:citation sg:pub.10.1007/s00234-002-0762-6
5 schema:datePublished 2018-12
6 schema:datePublishedReg 2018-12-01
7 schema:description Introduction: Systemic thrombolytic therapy (STLT) with recombinant tissue plasminogen activator (rtPA) is the “gold standard” of reperfusion therapy in certain patients with ischemic stroke during the first 4.5 h after stroke onset. Objective: To assess the clinical (severity of neurological symptoms) and laboratory (complete blood cell count test) factors that affect the disease outcome after STLT. Materials and methods: Seventy patients (48 males and 22 females) aged 61 [54; 69] years with ischemic stroke who received rtPA therapy at a dose of 0.9 mg/kg were prospectively studied. Blood for the complete blood count test including neutrophil and lymphocyte counts was sampled before the thrombolytic therapy. The severity of neurological impairment was assessed using the NIH Stroke Scale (NIHSS). The functional outcome was assessed 3 months after stroke with the modified Rankin scale (mRS). ROC analysis was used to reveal factors of unfavorable outcome in acute phase of ischemic stroke (mRS score ≥ 3). Results: Severity of neurological deficit was assessed according to the NIHSS at admission was 15 [11; 17] points. Time between the manifestation of neurological symptoms and admission to the hospital was 138 [117; 170] min, and time between admission and initiation of STLT (the door-to-needle time), was 40 [30; 55] min. An unfavourable functional outcome of systemic thrombolytic therapy can be predicted according to the results of ROC analysis: the NIHSS score upon admission 12 or higher (sensitivity, 94%; specificity, 57%); neutrophil count, >7.8 × 109/L (sensitivity, 45.5%; specificity, 90.6%); lymphocyte count < 1.8 × 109/L (sensitivity, 81.8%; specificity, 59.4%). Conclusions: Personalized approach to systemic thrombolytic therapy may help to predict its effectiveness and contribute the development of more reliable strategies of patient management. Patients with potentially unfavorable outcome after intravenous thrombolysis can be the target group for mechanical reperfusion techniques such as thrombus extraction.
8 schema:genre article
9 schema:inLanguage en
10 schema:isAccessibleForFree false
11 schema:isPartOf N92e7ab78425d436483eaf03c215a930c
12 Nadcc0922720544c9bafb0b4e7adc737d
13 sg:journal.1085127
14 schema:keywords NIH Stroke Scale
15 NIHSS score
16 ROC analysis
17 Rankin Scale
18 Stroke Scale
19 activator
20 acute phase
21 admission
22 admission 12
23 analysis
24 approach
25 blood
26 blood count test
27 certain patients
28 complete blood count test
29 count test
30 counts
31 deficits
32 development
33 disease outcome
34 dose
35 effectiveness
36 extraction
37 factors
38 functional outcome
39 gold standard
40 group
41 hospital
42 impairment
43 initiation
44 initiation of STLT
45 intravenous thrombolysis
46 ischemic stroke
47 laboratory factors
48 lymphocyte count
49 management
50 manifestations
51 materials
52 mechanical reperfusion techniques
53 method
54 min
55 modified Rankin Scale
56 months
57 neurological deficits
58 neurological impairment
59 neurological symptoms
60 neutrophil count
61 neutrophils
62 onset
63 outcomes
64 patient management
65 patients
66 personalized approach
67 personified approach
68 phase
69 plasminogen activator
70 point
71 recombinant tissue plasminogen activator
72 reliable strategy
73 reperfusion techniques
74 reperfusion therapy
75 results
76 rtPA therapy
77 scale
78 scores
79 severity
80 standards
81 strategies
82 stroke
83 stroke onset
84 symptoms
85 systemic thrombolytic therapy
86 target group
87 technique
88 test
89 therapy
90 thrombolysis
91 thrombolytic therapy
92 thrombus extraction
93 time
94 tissue plasminogen activator
95 unfavorable outcome
96 unfavourable functional outcome
97 years
98 schema:name Personified Approaches to Reperfusion Therapy of Ischemic Stroke
99 schema:pagination 869-874
100 schema:productId N0dc9d1c2acd64c4b929de031fff83536
101 N2b05677237fd457bb44be10d601f0c37
102 schema:sameAs https://app.dimensions.ai/details/publication/pub.1112766608
103 https://doi.org/10.1134/s0362119718080030
104 schema:sdDatePublished 2021-11-01T18:33
105 schema:sdLicense https://scigraph.springernature.com/explorer/license/
106 schema:sdPublisher N4cef4599f49c43a3b5006399aa2fb267
107 schema:url https://doi.org/10.1134/s0362119718080030
108 sgo:license sg:explorer/license/
109 sgo:sdDataset articles
110 rdf:type schema:ScholarlyArticle
111 N0dc9d1c2acd64c4b929de031fff83536 schema:name doi
112 schema:value 10.1134/s0362119718080030
113 rdf:type schema:PropertyValue
114 N15f8725773a747658a02320e290361b5 rdf:first sg:person.0577166305.86
115 rdf:rest Nc9e48d8240154ebeab96ed94a56fcbc7
116 N1c2d96b8b1a84911bec9e40b310df28f rdf:first sg:person.011622234404.36
117 rdf:rest N6f5b3e12d13f4ca7a21906b69ecb3511
118 N2b05677237fd457bb44be10d601f0c37 schema:name dimensions_id
119 schema:value pub.1112766608
120 rdf:type schema:PropertyValue
121 N4cef4599f49c43a3b5006399aa2fb267 schema:name Springer Nature - SN SciGraph project
122 rdf:type schema:Organization
123 N6f5b3e12d13f4ca7a21906b69ecb3511 rdf:first sg:person.01060542443.55
124 rdf:rest Nc1f68507c010450fbde78f1de10a0c50
125 N92e7ab78425d436483eaf03c215a930c schema:issueNumber 8
126 rdf:type schema:PublicationIssue
127 Nadcc0922720544c9bafb0b4e7adc737d schema:volumeNumber 44
128 rdf:type schema:PublicationVolume
129 Nc1f68507c010450fbde78f1de10a0c50 rdf:first sg:person.010223501057.42
130 rdf:rest N15f8725773a747658a02320e290361b5
131 Nc9e48d8240154ebeab96ed94a56fcbc7 rdf:first sg:person.015231126745.66
132 rdf:rest Nf134e8f465fd40c194568d947c7387c0
133 Nf134e8f465fd40c194568d947c7387c0 rdf:first sg:person.010206350616.20
134 rdf:rest rdf:nil
135 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
136 schema:name Medical and Health Sciences
137 rdf:type schema:DefinedTerm
138 anzsrc-for:1102 schema:inDefinedTermSet anzsrc-for:
139 schema:name Cardiorespiratory Medicine and Haematology
140 rdf:type schema:DefinedTerm
141 sg:journal.1085127 schema:issn 0362-1197
142 1608-3164
143 schema:name Human Physiology
144 schema:publisher Pleiades Publishing
145 rdf:type schema:Periodical
146 sg:person.010206350616.20 schema:affiliation grid-institutes:grid.465332.5
147 schema:familyName Piradov
148 schema:givenName M. A.
149 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010206350616.20
150 rdf:type schema:Person
151 sg:person.010223501057.42 schema:affiliation grid-institutes:grid.477034.3
152 schema:familyName Gafarova
153 schema:givenName M. E.
154 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.010223501057.42
155 rdf:type schema:Person
156 sg:person.01060542443.55 schema:affiliation grid-institutes:grid.465332.5
157 schema:familyName Maksimova
158 schema:givenName M. Yu.
159 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01060542443.55
160 rdf:type schema:Person
161 sg:person.011622234404.36 schema:affiliation grid-institutes:grid.477034.3
162 schema:familyName Domashenko
163 schema:givenName M. A.
164 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011622234404.36
165 rdf:type schema:Person
166 sg:person.015231126745.66 schema:affiliation grid-institutes:grid.465332.5
167 schema:familyName Antonova
168 schema:givenName K. V.
169 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.015231126745.66
170 rdf:type schema:Person
171 sg:person.0577166305.86 schema:affiliation grid-institutes:grid.465332.5
172 schema:familyName Tanashyan
173 schema:givenName M. M.
174 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0577166305.86
175 rdf:type schema:Person
176 sg:pub.10.1007/s00234-002-0762-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029241563
177 https://doi.org/10.1007/s00234-002-0762-6
178 rdf:type schema:CreativeWork
179 grid-institutes:grid.465332.5 schema:alternateName Research Center of Neurology, 125367, Moscow, Russia
180 schema:name Research Center of Neurology, 125367, Moscow, Russia
181 rdf:type schema:Organization
182 grid-institutes:grid.477034.3 schema:alternateName Botkin City Clinical Hospital, 125284, Moscow, Russia
183 Vorokhobov City Clinical Hospital no. 67, Moscow, Russia
184 schema:name Botkin City Clinical Hospital, 125284, Moscow, Russia
185 Vorokhobov City Clinical Hospital no. 67, Moscow, Russia
186 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...